^
Association details:
| Biomarker: | AR overexpression |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | NXP800 (GCN2 activator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of HSF1 demonstrates therapeutic efficacy in preclinical models of cholangiocarcinoma
Published date:
03/15/2023
Excerpt:
Mice were then treated with either NXP800 (35 mg/kg), in the treatment arm...Molecular characterization of the tumor identified NRAS Q61 mutation, FGFR1 and FGFR2 overexpression, androgen receptor overexpression...Treatment with NXP800 was associated with a statistically significant decrease in tumor size compared to control tumor bearing mice, with a mean difference of the delta in tumor volume (852.6 mm3; 95% CI: 321 - 1384; P-value = 0.0057)...NXP800, a HSF1 inhibitor, demonstrated significant therapeutic activity in a cholangiocarcinoma PDX.
